CNBC contributor Michael Santoli looks at companies with dividend yield that is higher than their corporate debt.» Read More
Investors can’t help but wonder what’s the best way to play Pharma after Pfizer said it would buy rival Wyeth for $60 billion, a 20% premium!
Ever wonder how these people decide which stock's a buy and which is a sell? Now you know.
Dr. Steven Nissen, the cardiology chief at the Cleveland Clinic, reportedly remains on the shortlist to possibly become the next FDA Commissioner. Some analysts believe if Dr. Nissen gets the nod there could be a negative knee-jerk reaction in the big pharma sector stocks.
The Dow ended below 8,000 for the first time in two months as bank stocks took a beating over profit worries.
Stocks paused briefly as Barack Obama was sworn in as the 44th president but resumed their slide as banks took a beating over profit worries.
The FDA giveth and the FDA taketh away. Yesterday the agency handed Merck a little bit of a break with what could be interpreted as an endorsement, of sorts. But then this morning the FDA issued another delay in deciding whether to approve the company's Gardasil vaccine.
It’s Beijing, and not Washington, that’s going to get us out of this worldwide recession, he says.
Merck, Lilly and Pfizer are all trading substantially higher. Will this bear market remedy keep working in the new year?
Stocks finished higher Friday on a day when Wall Street looked like a ghost town, but the week ended without a visit from a much-anticipated Santa Claus rally.
Public perception and reality are often at odds, and Neil Hennessy sees that to be the case in the stock market today. He urged investors to step back, realize that they can't make money buying Treasurys, and get their money flowing back into stocks.
As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.
The final numbers for Q3 GDP came in this morning, showing the economy contracted by 0.5%. The forecast for Q4 is that it will drop significantly more. There are, however, areas of the economy that are growing...
Historically, December has been the strongest month of the year on average for the Dow. So far this year, the Dow is down 2.8% month-to-date. Will we see a Santa Claus rally this year?
The stock market ended both the day and the week essentially flat, with the twin stimuli of interest rate cuts and an automaker bailout unable to overcome a weakening economy and pessimism about the future of the banking system.
Stocks advanced Friday after Bush announced details of a rescue plan for auto makers.
Drugmaker Bristol-Myers Squibb said Tuesday it will eliminate another 10 percent of its work force through 2010 as it works to pare costs before it loses patent protection on key drugs.
Drugmaker Bristol-Myers Squibb became the latest big company to announce layoffs, saying it will eliminate another 10 percent of its work force through 2010.
For months now several analysts have been pointing out that despite big pharma's many problems some of the companies still pay healthy dividends. And when T-bills are offering next to nothing, a solid dividend yield in these rough and tumble times is a good thing.
The Consumer Price Index had its biggest one month drop ever. Here is a breakdown of the inflation benchmark to show you where costs are falling most.
Pharma companies are usually considered safety plays. But might they also be growth stocks in disguise?